<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04421456</url>
  </required_header>
  <id_info>
    <org_study_id>GWAP19030</org_study_id>
    <secondary_id>2019-003369-16</secondary_id>
    <nct_id>NCT04421456</nct_id>
  </id_info>
  <brief_title>Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment</brief_title>
  <official_title>A Randomized, Double-blind, Parallel-group Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GW Research Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GW Research Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to evaluate the efficacy, safety, and tolerability of GWP42003-P&#xD;
      versus placebo in participants with schizophrenia experiencing inadequate response to ongoing&#xD;
      antipsychotic treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 18, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change from Baseline in the Positive and Negative Symptoms Scale (PANSS) Total (PANSS-T) Score</measure>
    <time_frame>From Baseline up to Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change from Baseline in the Clinical Global Impression of Severity (CGI-S) Score</measure>
    <time_frame>From Baseline up to Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Global Impression of Improvement (CGI-I) Score</measure>
    <time_frame>From Baseline up to Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change from Baseline in the PANSS Positive Subscale (PANSS-P) Score</measure>
    <time_frame>From Baseline up to Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change from Baseline in the PANSS Negative Subscale (PANSS-N) Score</measure>
    <time_frame>From Baseline up to Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change from Baseline in the PANSS General Subscale (PANSS-G) Score</measure>
    <time_frame>From Baseline up to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in Body Weight</measure>
    <time_frame>From Baseline up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in Body Mass Index (BMI)</measure>
    <time_frame>From Baseline up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in Waist Circumference</measure>
    <time_frame>From Baseline up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in Blood Pressure</measure>
    <time_frame>From Baseline up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in Heart Rate</measure>
    <time_frame>From Baseline up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in Respiratory Rate</measure>
    <time_frame>From Baseline up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in Temperature</measure>
    <time_frame>From Baseline up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs) and Adverse Drug Reactions (ADRs)</measure>
    <time_frame>From Baseline up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in the Extrapyramidal Symptom Rating Scale (ESRS) Score, as An Assessment of Extrapyramidal Symptoms</measure>
    <time_frame>From Baseline up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Clinical Laboratory Test Results</measure>
    <time_frame>From Baseline up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant 12 Lead Electrocardiogram (ECG) Parameter Values</measure>
    <time_frame>From Baseline up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in the Calgary Depression Scale for Schizophrenia (CDSS) Score</measure>
    <time_frame>From Baseline up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in the Columbia Suicide Severity Rating Scale (C-SSRS) Score, as An Assessment of Suicidality</measure>
    <time_frame>From Baseline up to Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">366</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>GWP42003-P 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GWP42003-P 300 milligrams (mg) per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GWP42003-P 1000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GWP42003-P 1000 mg per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GWP42003-P</intervention_name>
    <description>oral solution containing 100 milligrams per milliliter (mg/mL) cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol (10% v/v), with sweetener (sucralose), and strawberry flavoring</description>
    <arm_group_label>GWP42003-P 1000 mg</arm_group_label>
    <arm_group_label>GWP42003-P 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral solution containing the excipients sesame oil and anhydrous ethanol, with added β-carotene, sweetener (sucralose), and strawberry flavoring</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female 18 to 55 years of age at the time of signing the Informed Consent Form&#xD;
             (ICF)&#xD;
&#xD;
          -  Willing and able to give informed consent for participation in the trial&#xD;
&#xD;
          -  Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnosis of&#xD;
             schizophrenia, confirmed by the Mini International Neuropsychiatric Interview (MINI)&#xD;
&#xD;
          -  Clinically stable outpatient&#xD;
&#xD;
          -  Positive and Negative Symptoms Scale (PANSS) Total (PANSS-T) score of ≥ 60 and &lt; 110&#xD;
             at screening and baseline visits&#xD;
&#xD;
          -  Score of ≥ 4 for at least 2 of the following PANSS items: delusions (P1), conceptual&#xD;
             disorganization (P2), hallucinatory behavior (P3), suspiciousness (P6), somatic&#xD;
             concern (G1), or unusual thought content (G9) at screening visit&#xD;
&#xD;
          -  Score ≥ 4 (at least moderately ill) on the Clinical Global Impression of Severity&#xD;
             (CGI-S) at screening visit.&#xD;
&#xD;
          -  Undergoing treatment with at least 1 antipsychotic medication with no change in&#xD;
             dosing, supported by documentation, for at least 8 weeks prior to screening and no&#xD;
             change in antipsychotic medication dosing planned throughout the trial&#xD;
&#xD;
          -  Taking a maximum of 2 antipsychotic medications. For participants taking oral&#xD;
             antipsychotic medications only, the sum of primary and secondary antipsychotic&#xD;
             medications is ≤ 30 milligrams (mg)/day of oral olanzapine equivalents. For&#xD;
             participants taking long-acting injectable antipsychotic medications, the dose is&#xD;
             within the range approved and any secondary oral antipsychotic medications is ≤ 5&#xD;
             mg/day of oral olanzapine equivalents.&#xD;
&#xD;
          -  Documented response (at least partially) to treatment with current antipsychotic&#xD;
             medications (e.g., treatment of recent exacerbation of psychotic symptoms)&#xD;
&#xD;
          -  On a stable dose if taking concomitant psychotropic medications and within allowed&#xD;
             limits, including antidepressants, anxiolytics, anticholinergics and/or antiepileptics&#xD;
             for at least 4 weeks prior to screening (dose reductions ≤ 25% of total dose are&#xD;
             permitted) with no plans to change dosing during the trial (i.e., from screening&#xD;
             onwards). Valproic acid or any prescribed valproate product (valproate semisodium or&#xD;
             valproate sodium) is disallowed within 4 weeks (i.e., more than 5 half lives) prior to&#xD;
             the baseline visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Diagnosis and Psychiatric History&#xD;
&#xD;
          -  Recent (within the last 3 months prior to screening) diagnosis of panic disorder,&#xD;
             depressive episode, or other comorbid psychiatric conditions based on the MINI for&#xD;
             Psychotic Disorders Studies (or DSM-5) OR has PANSS item G6 score of ≥ 5 (depression)&#xD;
             at screening.&#xD;
&#xD;
          -  Any psychiatric disorder that may interfere with the conduct of this trial, including&#xD;
             but not limited to attention deficit hyperactivity disorder, pervasive developmental&#xD;
             disorder, intellectual disability, personality disorder that might interfere with&#xD;
             compliance or increase suicidal risk, manic or hypomanic episode, or any other&#xD;
             psychotic disorder, as defined in the DSM-5&#xD;
&#xD;
          -  Current diagnosis or a history of substance use disorder according to DSM-5 criteria&#xD;
             within 6 months prior to screening or prior chronic substance abuse judged likely to&#xD;
             recur during the trial period by the investigator. Nicotine use or occasional cannabis&#xD;
             use (≤ 3 days per week recreational cannabis use) is acceptable. Corroboration of the&#xD;
             participant's frequency of cannabis use by an adult informant (e.g., family member,&#xD;
             social worker, caseworker, residential facility staff, or nurse), should be obtained&#xD;
             if the participant has a positive urine test for Δ9-tetrahydrocannabinol at screening.&#xD;
&#xD;
          -  A positive drug screen for opiates, methadone, cocaine, amphetamines (including&#xD;
             ecstasy), or barbiturates; a repeat drug screen may be done to verify the result.&#xD;
&#xD;
          -  Any history of suicidal behavior or any suicidal ideation of type 4 or 5 on the adult&#xD;
             C-SSRS or within 1 month prior to screening&#xD;
&#xD;
        Treatment History&#xD;
&#xD;
          -  Treatment-resistant schizophrenia as judged by the treating physician and as defined&#xD;
             by having previously demonstrated no response to &gt; 2 trials of antipsychotic trial&#xD;
             medications at therapeutic doses or required clozapine therapy due to non-response to&#xD;
             antipsychotic therapy within the previous 6 months.&#xD;
&#xD;
          -  Based on the investigator assessment, current antipsychotic medication blood levels&#xD;
             are below the therapeutic range if therapeutic drug monitoring is available for the&#xD;
             antipsychotic(s) prescribed for the participant; or there is no documentation&#xD;
             confirming the administration of long-acting injectable antipsychotic medication&#xD;
             within the approved dose range and as prescribed by the treating physician.&#xD;
&#xD;
        Past and Current Medical History&#xD;
&#xD;
          -  History of moderate or severe head trauma (for example, loss of consciousness for more&#xD;
             than 15 minutes) or other neurological disorders (including epilepsy),&#xD;
             neurodegenerative disorder (Alzheimer's disease, Parkinson's disease, multiple&#xD;
             sclerosis, Huntington's disease, etc.) or systemic medical diseases that are, in the&#xD;
             opinion of the investigator, likely to interfere with the conduct of the trial or&#xD;
             confound the trial assessments&#xD;
&#xD;
          -  Tardive dyskinesia (TD) that is moderate to severe (i.e., a score of &gt; 21 on the&#xD;
             dyskinesia subscale of the Extrapyramidal Symptom Rating Scale [ESRS] at screening) or&#xD;
             requires treatment&#xD;
&#xD;
          -  Any other significant disease, disorder, pending court proceedings or social&#xD;
             circumstances which, in the opinion of the investigator, may either put the&#xD;
             participant at risk because of participation in the trial, may influence the result of&#xD;
             the trial, or may affect the participant's ability to take part in the trial.&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Any known or suspected hypersensitivity to cannabinoids or any of the excipients of&#xD;
             the investigational medicinal product, such as sesame seed oil&#xD;
&#xD;
          -  One or more laboratory values outside the normal range, based on the blood or urine&#xD;
             samples taken at the screening visit, that are considered by the investigator to be&#xD;
             clinically significant; or impaired hepatic function at screening, defined as serum&#xD;
             alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 2 × upper limit&#xD;
             of normal (ULN) or total bilirubin (TBL) &gt; 1.5 × ULN or international normalized ratio&#xD;
             (INR) &gt; 1.2 (TBL ULN parameter not applicable for participants diagnosed with&#xD;
             Gilbert's disease)&#xD;
&#xD;
          -  Currently using or within 3 months of screening has used cannabidiol (CBD) oil or&#xD;
             purified CBD preparations and is unwilling to abstain for the duration of the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>+44 (0) 1223 266 800</phone>
    <email>medinfo@gwpharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Medical Information</last_name>
    <phone>(833) 424-6724</phone>
    <email>medinfo@greenwichbiosciences.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Bentonville</city>
        <state>Arkansas</state>
        <zip>72712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211-3702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Lemon Grove</city>
        <state>California</state>
        <zip>91945</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94607-3900</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Pico Rivera</city>
        <state>California</state>
        <zip>90660-4920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33770</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Lauderhill</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Lincolnwood</city>
        <state>Illinois</state>
        <zip>60712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70629</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Gaithersburg</city>
        <state>Maryland</state>
        <zip>20877</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Cedarhurst</city>
        <state>New York</state>
        <zip>11516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78754</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <zip>75080</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007-4879</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Belchatow</city>
        <zip>97-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Chelmno</city>
        <zip>86-200</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-438</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-546</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-832</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Kielce</city>
        <zip>25-411</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Kobierzyce</city>
        <zip>55-040</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-369</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Pruszcz Gdanski</city>
        <zip>83-000</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Warsaw</city>
        <zip>02-957</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-227</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>54-617</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site#1</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site#2</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site#3</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site#4</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site#1</name>
      <address>
        <city>Kovin</city>
        <zip>26220</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site#2</name>
      <address>
        <city>Kovin</city>
        <zip>26220</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site#1</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site#2</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site#3</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Nis</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Alcorcón</city>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Oviedo</city>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Salamanca</city>
        <zip>37005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Valladolid</city>
        <zip>47016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Vitoria-Gasteiz</city>
        <zip>01009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 27, 2020</study_first_submitted>
  <study_first_submitted_qc>June 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GWP42003-P</keyword>
  <keyword>adjunctive therapy</keyword>
  <keyword>inadequate response to ongoing antipsychotic treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

